CEO
David Seaburg
Employees
43
Industry
Biological Product (except Diagnostic) Manufacturing
polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Lisa Levin
June 15, 2023 | 12:05 pm
Portfolio Pulse from Benzinga Insights
June 13, 2023 | 1:07 pm
Portfolio Pulse from Lisa Levin
June 13, 2023 | 12:15 pm
Portfolio Pulse from Benzinga Insights
June 08, 2023 | 5:32 pm
Portfolio Pulse from Lisa Levin
June 08, 2023 | 5:06 pm
Portfolio Pulse from Benzinga Insights
June 08, 2023 | 1:07 pm
Portfolio Pulse from Lisa Levin
June 08, 2023 | 12:23 pm
Portfolio Pulse from Lisa Levin
June 07, 2023 | 6:53 pm
Portfolio Pulse from Benzinga Newsdesk
June 07, 2023 | 6:37 pm
Portfolio Pulse from Lisa Levin
June 07, 2023 | 6:03 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.